EP0458835A1 - Spendevorrichtung - Google Patents

Spendevorrichtung

Info

Publication number: EP0458835A1
Authority: EP; European Patent Office
Prior art keywords: capsule; water; piece; cross linked; constructed
Prior art date: 1989-02-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP90903196A

Other languages

English (en)

French (fr)

Inventor

Abdul Rashid

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

National Research Development Corp UK

Original Assignee

National Research Development Corp UK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-16

Filing date

1990-02-15

Publication date

1991-12-04

1990-02-15 Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK

1991-12-04 Publication of EP0458835A1 publication Critical patent/EP0458835A1/de

Status Pending legal-status Critical Current

Links

239000002775 capsule Substances 0.000 claims abstract description 74
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 65
239000000463 material Substances 0.000 claims abstract description 59
239000011149 active material Substances 0.000 claims abstract description 24
238000013270 controlled release Methods 0.000 claims abstract description 10
239000006186 oral dosage form Substances 0.000 claims abstract description 6
239000000017 hydrogel Substances 0.000 claims description 30
-1 polyethylene Polymers 0.000 claims description 19
239000002552 dosage form Substances 0.000 claims description 8
238000000926 separation method Methods 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 5
230000008961 swelling Effects 0.000 claims description 5
239000000020 Nitrocellulose Substances 0.000 claims description 4
239000012948 isocyanate Substances 0.000 claims description 4
150000002513 isocyanates Chemical class 0.000 claims description 4
229920001220 nitrocellulos Polymers 0.000 claims description 4
229920002635 polyurethane Polymers 0.000 claims description 4
239000004814 polyurethane Substances 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 3
229920002301 cellulose acetate Polymers 0.000 claims description 3
239000002702 enteric coating Substances 0.000 claims description 3
238000009505 enteric coating Methods 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
229920002126 Acrylic acid copolymer Polymers 0.000 claims description 2
229920002307 Dextran Polymers 0.000 claims description 2
108010010803 Gelatin Proteins 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
239000004743 Polypropylene Substances 0.000 claims description 2
239000004793 Polystyrene Substances 0.000 claims description 2
238000010521 absorption reaction Methods 0.000 claims description 2
125000001033 ether group Chemical group 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
230000002209 hydrophobic effect Effects 0.000 claims description 2
229920001778 nylon Polymers 0.000 claims description 2
229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
229920002401 polyacrylamide Polymers 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
229920001155 polypropylene Polymers 0.000 claims description 2
229920002223 polystyrene Polymers 0.000 claims description 2
229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
239000004800 polyvinyl chloride Substances 0.000 claims description 2
229920000915 polyvinyl chloride Polymers 0.000 claims description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
150000004292 cyclic ethers Chemical group 0.000 claims 2
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 1
101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 claims 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
150000001299 aldehydes Chemical class 0.000 claims 1
229920003020 cross-linked polyethylene Polymers 0.000 claims 1
239000004703 cross-linked polyethylene Substances 0.000 claims 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
239000004926 polymethyl methacrylate Substances 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
229920002554 vinyl polymer Polymers 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 8
238000002360 preparation method Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 8
239000000203 mixture Substances 0.000 description 8
229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
229920001477 hydrophilic polymer Polymers 0.000 description 7
230000000694 effects Effects 0.000 description 6
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
238000010276 construction Methods 0.000 description 4
QMNFFXRFOJIOKZ-UHFFFAOYSA-N cycloguanil Chemical compound CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1 QMNFFXRFOJIOKZ-UHFFFAOYSA-N 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
230000035699 permeability Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
238000010382 chemical cross-linking Methods 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 3
239000008187 granular material Substances 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000000843 powder Substances 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
229940124575 antispasmodic agent Drugs 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
229950004734 cycloguanil Drugs 0.000 description 2
230000001934 delay Effects 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000005056 polyisocyanate Substances 0.000 description 2
229920005604 random copolymer Polymers 0.000 description 2
239000000376 reactant Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
229960004306 sulfadiazine Drugs 0.000 description 2
208000037972 tropical disease Diseases 0.000 description 2
GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
PWUMRNFCZFZXAE-UHFFFAOYSA-N 1,3-bis(3-carbamimidoylphenyl)urea;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=CC(NC(=O)NC=2C=C(C=CC=2)C(N)=N)=C1 PWUMRNFCZFZXAE-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
BJELTSYBAHKXRW-UHFFFAOYSA-N 2,4,6-triallyloxy-1,3,5-triazine Chemical compound C=CCOC1=NC(OCC=C)=NC(OCC=C)=N1 BJELTSYBAHKXRW-UHFFFAOYSA-N 0.000 description 1
FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
241000238421 Arthropoda Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920008347 Cellulose acetate propionate Polymers 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
208000026368 Cestode infections Diseases 0.000 description 1
208000022636 Cestode infectious disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
206010009344 Clonorchiasis Diseases 0.000 description 1
MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000242711 Fasciola hepatica Species 0.000 description 1
241000243976 Haemonchus Species 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
241000256602 Isoptera Species 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000243789 Metastrongyloidea Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 description 1
229930192627 Naphthoquinone Natural products 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
206010062701 Nematodiasis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
241000223777 Theileria Species 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
229920005603 alternating copolymer Polymers 0.000 description 1
ZPFXAOWNKLFJDN-UHFFFAOYSA-N alverine Chemical compound C=1C=CC=CC=1CCCN(CC)CCCC1=CC=CC=C1 ZPFXAOWNKLFJDN-UHFFFAOYSA-N 0.000 description 1
229960000845 alverine Drugs 0.000 description 1
DKVNAGXPRSYHLB-UHFFFAOYSA-N amoscanate Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=CC=C(N=C=S)C=C1 DKVNAGXPRSYHLB-UHFFFAOYSA-N 0.000 description 1
229950008286 amoscanate Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
229940125688 antiparkinson agent Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
201000008680 babesiosis Diseases 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
229960005361 cefaclor Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
MGDIRAXSDLCQGC-UHFFFAOYSA-N chembl1999063 Chemical compound O=C1C2=CC=CC=C2C(=O)C(O)=C1CCCCCCCCC1CCCCC1 MGDIRAXSDLCQGC-UHFFFAOYSA-N 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
229960004287 clofazimine Drugs 0.000 description 1
229950004178 closantel Drugs 0.000 description 1
ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000001723 curing Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960000860 dapsone Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940000033 dermatological agent Drugs 0.000 description 1
239000003241 dermatological agent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000005553 drilling Methods 0.000 description 1
244000078703 ectoparasite Species 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
239000003000 extruded plastic Substances 0.000 description 1
208000006275 fascioliasis Diseases 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
230000004907 flux Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000003898 horticulture Methods 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229950008312 menoctone Drugs 0.000 description 1
229960000901 mepacrine Drugs 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
238000013008 moisture curing Methods 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
VKXQZROIIKPELG-UHFFFAOYSA-N n-(6-methoxyquinolin-8-yl)-n'-propan-2-ylpentane-1,5-diamine Chemical compound N1=CC=CC2=CC(OC)=CC(NCCCCCNC(C)C)=C21 VKXQZROIIKPELG-UHFFFAOYSA-N 0.000 description 1
150000002791 naphthoquinones Chemical class 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
230000001069 nematicidal effect Effects 0.000 description 1
239000005645 nematicide Substances 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229950009635 pentaquine Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000009702 powder compression Methods 0.000 description 1
229960002957 praziquantel Drugs 0.000 description 1
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
229960005179 primaquine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
PCZFVTPRFQOIND-RSAXXLAASA-M sodium;11-[(1r)-cyclopent-2-en-1-yl]undecanoate Chemical compound [Na+].[O-]C(=O)CCCCCCCCCC[C@@H]1CCC=C1 PCZFVTPRFQOIND-RSAXXLAASA-M 0.000 description 1
229960000260 solasulfone Drugs 0.000 description 1
WAGUNVVOQBKLDL-UHFFFAOYSA-J solasulfone Chemical compound [Na+].[Na+].[Na+].[Na+].C=1C=C(S(=O)(=O)C=2C=CC(NC(CC(C=3C=CC=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)=CC=2)C=CC=1NC(S(=O)(=O)[O-])CC(S([O-])(=O)=O)C1=CC=CC=C1 WAGUNVVOQBKLDL-UHFFFAOYSA-J 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
229960005158 sulfamethizole Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229920001169 thermoplastic Polymers 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
229960003386 triazolam Drugs 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1
229960000820 zopiclone Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

the devices of this invention combine or utilise this release profile with the controlled release of active material over the' period before and/or after the sharp pulsed release.
the device of the present Invention may also be combined with another dosage form in a single capsule which will qombine the release profile of the device of this invention with that of the other dosage form.
two separate devices of this invention designed to have different delay times before the release of the active material may be joined end to end so that the active materials are separated by an impermeable wall.
a device of this invention may be joined to or combined with any other suitable controlled release device (of appropriate dimensions).
N-vinylpyrrol1dones cross-linked cellulosic derivatives especially those known to be useful as tablet dislntegrants
cross-linked dextrans especially those known to * be use' ul for column separations and wound healing
cross-linked hydroxyethyl ethacrylates especially those known to be useful in contact lenses
cross-linked gelatins and starches hydrogels comprising cross-linked (meth)acrylic acid copolymers and their salts
cross-linked polyacrylamides and cross-linked poly(ethylene glycols) cross-linked polyacrylamides and cross-linked poly(ethylene glycols).
Specific classes of drug which may be utilised in a device of the invention include hypnotics, sedatives, tranquiUsers, anti-pyretics, anti-Inflammatory agents, anti-histamines, anti-tussives, anti-convulsants, anti-asthmatics, muscle relaxants, anti-tumour agents, for example those for the treatment of malignant neoplasia, local anaesthetics, anti-Parkinson agents, topical or dermatological agents, diuretics, for example those containing potassium, such as potassium iodide, preparations for the treatment of mental illness, for example preparations containing lithium for use in the treatment of manic depression or containing prostaglandlns for the treatment of schizophrenia, anti-spasmodics, anti-ulcer agents, ⁇ l blockers such as atenolol and metoprolol; calcium antagonists such as nifedlpine and nitrendipine, ACE . ⁇ inhibitors such
the devices of this invention are suited to treatment, both prophylactic and therapeutic, of tropical diseases; for example malaria, leprosy, schistoso lasis and clonorchiasis.
drugs which can be used as biologically active substance in pulsed release devices of this invention for the treatment of these and other tropical diseases include quinine, sulphonamides, rlfamycin, clofazimine, thiambutasine, chlorphenyl derivatives, chlorguamide, cycloguanil, pyr1metham1ne, sulphadiazine, trimethoprlm, quinoline derivatives such as pa aquine, chloroqulne, pentaquine, primaquine and a odiquine, pararosaniUne, sulphamethizole, quinacrine, dapsone, sodium sulphoxone, sulphetrone, sodium hydnocarpate and sodium chaulmoograte
Any conventional enteric coating agent may be employed, for " " ex ' ample cellulose acetate phthalate, polyvinylacetate phthalate hydroxypropylmethylcellulose phthalate and pH sensitive polyacrylate and polymethacrylate derivates.
hydrogels may also be employed as- the water swellable material which is contained within the capsule. Those hydrogels which exhibit a higher degree of swelling are preferably used for this purpose. They may readily be prepared in the form of moulded monoliths or in particulate form. In the preferred devices the water swellable material and the plug may be constructed from the same material.
the hydrophilic polymer for example, polyethylene oxide, may also be foamed in a manner known jjer ⁇ e_.
suitable materials which may be used to coat the surface of the capsule include nitrocellulose, cellulose esters, ethers and acetals, polymethacr late copolymers, polyurethanes, air curing coatings " such as alkyd resins and moisture curing coatings such as polyurethanes containing an excess of isocyanate groups.

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Sampling And Sample Adjustment (AREA)
Formation And Processing Of Food Products (AREA)
Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Molding Of Porous Articles (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Refuse Collection And Transfer (AREA)
Seal Device For Vehicle (AREA)
Nozzles (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

EP90903196A 1989-02-16 1990-02-15 Spendevorrichtung Pending EP0458835A1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8903564		1989-02-16
GB898903564A GB8903564D0 (en)	1989-02-16	1989-02-16	Drug dispensing device

Publications (1)

Publication Number	Publication Date
EP0458835A1 true EP0458835A1 (de)	1991-12-04

Family

ID=10651816

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP90301608A Expired - Lifetime EP0384642B1 (de)	1989-02-16	1990-02-15	Wirkstoffabgabevorrichtung
EP90903196A Pending EP0458835A1 (de)	1989-02-16	1990-02-15	Spendevorrichtung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP90301608A Expired - Lifetime EP0384642B1 (de)	1989-02-16	1990-02-15	Wirkstoffabgabevorrichtung

Country Status (13)

Country	Link
EP (2)	EP0384642B1 (de)
JP (1)	JPH0735327B2 (de)
AT (1)	ATE98483T1 (de)
AU (1)	AU5096690A (de)
DE (1)	DE69005149T2 (de)
DK (1)	DK0384642T3 (de)
ES (1)	ES2049414T3 (de)
GB (2)	GB8903564D0 (de)
IE (1)	IE64154B1 (de)
NZ (1)	NZ232558A (de)
PT (1)	PT93168B (de)
WO (1)	WO1990009169A1 (de)
ZA (1)	ZA901156B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5938654A (en) *	1987-06-25	1999-08-17	Alza Corporation	Osmotic device for delayed delivery of agent
US5110597A (en) *	1987-06-25	1992-05-05	Alza Corporation	Multi-unit delivery system
US5443459A (en) *	1991-01-30	1995-08-22	Alza Corporation	Osmotic device for delayed delivery of agent
ZA92543B (en) *	1991-01-30	1992-10-28	Alza Corp	Osmotic device for delayed delivery of agent
US5387421A (en) *	1991-01-31	1995-02-07	Tsrl, Inc.	Multi stage drug delivery system
US5976571A (en) *	1991-01-31	1999-11-02	Port Systems, L.L.C.	Method for making a multi-stage drug delivery system
US5223265A (en) *	1992-01-10	1993-06-29	Alza Corporation	Osmotic device with delayed activation of drug delivery
CA2156726C (en) *	1993-02-26	2000-10-17	Paula Denise Davis	Bisacodyl dosage form
ATE234611T1 (de) *	1993-04-20	2003-04-15	Tsrl Inc	Mehrstufiges arzneistoffabgabesystem
US5498255A (en) *	1993-08-17	1996-03-12	Alza Corporation	Osmotic device for protracted pulsatile delivery of agent
GB9320733D0 (en) *	1993-10-08	1993-12-01	Scherer Corp R P	Controlled release device construction
GB9320732D0 (en) *	1993-10-08	1993-12-01	Scherer Corp R P	Controlled delivery of liquid
EP0724441A1 (de) *	1993-10-19	1996-08-07	The Procter & Gamble Company	Natriumpicosulfat enthaltende dosierungsform
US5516524A (en) *	1993-12-20	1996-05-14	The Procter & Gamble Company	Laxative compositions containing bulk fiber
GB9326267D0 (en) *	1993-12-23	1994-02-23	Scherer Corp R P	Expulsion of material
GB9326266D0 (en) *	1993-12-23	1994-02-23	Scherer Corp R P	Solubilising system
US5800422A (en) *	1995-06-02	1998-09-01	Alza Corporation	Osmotic device with delayed activation of drug delivery and complete drug release
US5902605A (en) *	1996-04-18	1999-05-11	Alza Corporation	Drug delivery device with minimal residual drug retention
CA2314486A1 (en)	1997-12-12	1999-06-24	Synoptik A/S	Container for timed release of substances
SE9704870D0 (sv)	1997-12-22	1997-12-22	Astra Ab	New pharmaceutical formulation I
US8454992B2 (en)	2007-10-15	2013-06-04	Capsugel Belgium Nv	Paneled capsule shells for release of pharmaceutical compositions
US8293159B2 (en)	2007-10-15	2012-10-23	Capsugel Belgium	Method and apparatus for manufacturing filled linkers
JP6097695B2 (ja)	2010-11-08	2017-03-15	アルビレオアクチエボラグ	Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
PT2739270T (pt) *	2011-08-01	2020-04-02	Hb Biotechnologies Corp	Cápsulas não digestíveis para a distribuição de materiais absorventes de fluido
WO2021071927A1 (en) *	2019-10-08	2021-04-15	Incube Labs, Llc	Controlled release formulation delivery device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB436236A (en) *	1934-04-26	1935-10-08	Karl Wilhelm Schmidt	Improvements in and relating to a therapeutic capsule
US3952741A (en) *	1975-01-09	1976-04-27	Bend Research Inc.	Controlled release delivery system by an osmotic bursting mechanism
GB8319766D0 (en) *	1983-07-22	1983-08-24	Graham N B	Controlled release device
GB8403138D0 (en) *	1984-02-07	1984-03-14	Graham N B	Sustained release of active ingredient
US4684524A (en) *	1984-03-19	1987-08-04	Alza Corporation	Rate controlled dispenser for administering beneficial agent
US4874388A (en) *	1987-06-25	1989-10-17	Alza Corporation	Multi-layer delivery system

1989
- 1989-02-16 GB GB898903564A patent/GB8903564D0/en active Pending
1990
- 1990-02-15 DE DE90301608T patent/DE69005149T2/de not_active Expired - Fee Related
- 1990-02-15 EP EP90301608A patent/EP0384642B1/de not_active Expired - Lifetime
- 1990-02-15 NZ NZ232558A patent/NZ232558A/xx unknown
- 1990-02-15 WO PCT/GB1990/000250 patent/WO1990009169A1/en not_active Ceased
- 1990-02-15 PT PT93168A patent/PT93168B/pt not_active IP Right Cessation
- 1990-02-15 ES ES90301608T patent/ES2049414T3/es not_active Expired - Lifetime
- 1990-02-15 GB GB9003502A patent/GB2230441B/en not_active Expired - Lifetime
- 1990-02-15 DK DK90301608.7T patent/DK0384642T3/da active
- 1990-02-15 ZA ZA901156A patent/ZA901156B/xx unknown
- 1990-02-15 EP EP90903196A patent/EP0458835A1/de active Pending
- 1990-02-15 JP JP2503361A patent/JPH0735327B2/ja not_active Expired - Lifetime
- 1990-02-15 IE IE55490A patent/IE64154B1/en not_active IP Right Cessation
- 1990-02-15 AT AT90301608T patent/ATE98483T1/de not_active IP Right Cessation
- 1990-02-15 AU AU50966/90A patent/AU5096690A/en not_active Abandoned

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9009169A1 *

Also Published As

Publication number	Publication date
NZ232558A (en)	1991-08-27
IE64154B1 (en)	1995-07-12
PT93168A (pt)	1990-08-31
PT93168B (pt)	1997-08-29
DK0384642T3 (da)	1994-01-24
EP0384642B1 (de)	1993-12-15
EP0384642A1 (de)	1990-08-29
AU5096690A (en)	1990-09-05
GB8903564D0 (en)	1989-04-05
JPH04503354A (ja)	1992-06-18
GB2230441B (en)	1993-05-12
ZA901156B (en)	1991-10-30
IE900554L (en)	1990-08-16
DE69005149D1 (de)	1994-01-27
WO1990009169A1 (en)	1990-08-23
ATE98483T1 (de)	1994-01-15
ES2049414T3 (es)	1994-04-16
GB2230441A (en)	1990-10-24
GB9003502D0 (en)	1990-04-11
JPH0735327B2 (ja)	1995-04-19
DE69005149T2 (de)	1994-04-07

Legal Events

Date	Code	Title	Description
1991-10-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1991-10-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
1991-12-04	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE
1991-12-11	17P	Request for examination filed	Effective date: 19910820
1992-04-08	XX	Miscellaneous (additional remarks)	Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 90301608.7/0384642 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 25.02.92.

Publication	Publication Date	Title
EP0384642B1 (de)	1993-12-15	Wirkstoffabgabevorrichtung
US6200600B1 (en)	2001-03-13	Controlled delay release device
EP0384646B1 (de)	1993-06-09	Wirkstoffabgabevorrichtung
Graham et al.	1984	Hydrogels for controlled drug delivery
US4814182A (en)	1989-03-21	Controlled release device
US5342624A (en)	1994-08-30	Dispensing device
WO1999040942A1 (en)	1999-08-19	Preparations with controlled release
AU646244B2 (en)	1994-02-17	Dispensing device
HU229962B1 (hu)	2015-03-30	Metformint tartalmazó nyújtott felszabadulású tabletta formájú gyógyszerkészítmény
EA026830B1 (ru)	2017-05-31	Осмотически активная система вагинальной доставки
US5474784A (en)	1995-12-12	Dispensing device
PL90109B1 (de)	1977-01-31
GB2243777A (en)	1991-11-13	Sustained release device